Related Experiment Video
Updated: Jun 9, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors
Felipe Galvez-Cancino1,2, Eileen E Parkes2,3, David R Withers4
1Laboratory of Immune-Regulation, NDM Centre for Immuno-Oncology, University of Oxford, Oxford, United Kingdom.
Abstract:
Next-generation anti-CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumor-restricted activation. The goal is to achieve robust antitumor activity without inducing systemic immune-related toxicity. See related article by Jhatakia et al., p. 3289.
Insights
Next-generation anti-CTLA-4 antibodies enhance tumor activity and reduce toxicity by using improved Fc-mediated function and conditional tumor activation. This approach aims for strong anti-tumor responses without systemic immune issues.
Area of Science:
- Immunotherapy
- Oncology
- Antibody Engineering
Background:
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key immune checkpoint inhibitor.
- Current anti-CTLA-4 therapies can cause significant systemic immune-related adverse events.
- Next-generation antibodies aim to improve the therapeutic window of CTLA-4 blockade.
Purpose of the Study:
- To design and evaluate novel anti-CTLA-4 antibodies with enhanced Fc-mediated effector functions.
- To achieve conditional tumor-restricted activation of these antibodies.
- To improve anti-tumor efficacy while minimizing systemic toxicity.
Main Methods:
- Engineering of anti-CTLA-4 antibodies with enhanced Fc regions.
- Incorporation of conditional activation mechanisms for tumor targeting.
- Preclinical testing in relevant tumor models to assess efficacy and toxicity.
Main Results:
- Demonstrated enhanced Fc-mediated effector functions in engineered antibodies.
- Showcased conditional tumor-restricted activation, limiting systemic exposure.
- Observed robust anti-tumor activity in preclinical models.
- Reported a favorable therapeutic index with reduced systemic immune-related toxicity.
Conclusions:
- Next-generation anti-CTLA-4 antibodies offer a promising strategy for cancer immunotherapy.
- Enhanced Fc function combined with conditional activation can improve efficacy and safety.
- These engineered antibodies represent a potential advancement in treating various cancers.
